Connor, Clark & Lunn Investment Management Ltd. Puma Biotechnology, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 368,455 shares of PBYI stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
368,455
Previous 354,514
3.93%
Holding current value
$1.11 Million
Previous $1.16 Million
18.7%
% of portfolio
0.0%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding PBYI
# of Institutions
101Shares Held
29MCall Options Held
50.6KPut Options Held
16.3K-
Vanguard Group Inc Valley Forge, PA3.64MShares$11 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$10.8 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$9.25 Million0.42% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.88MShares$8.7 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.97MShares$5.95 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $138M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...